NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DA-18-017 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-073 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HL-19-009 from the NIH Guide for Grants and Contracts. The Funding Opportunity Announcement (FOA) invites applications from qualified institutions willing to participate with NHLBI in the Cardiothoracic Surgical Trials Network (CTSN) as Linked Clinical Research Centers (LCRCs). The LCRCs will: (1) conduct collaborative randomized controlled trials (RCTs) and studies that evaluate cross specialty team-based care, interventions and novel therapies in the context of cardiac surgery but with broader relevance to cardiology and neurology; (2) utilize these findings to improve patient outcomes, and influence clinical practice, with benefits that are translatable to the general population; (3) conduct implementation research alongside RCTs to understand the best strategies for optimal uptake and sustainability and to bolster translation in areas of high disease burden; and (4) foster the next generation of clinical and implementation researchers.
Funding Opportunity RFA-HL-19-010 from the NIH Guide for Grants and Contracts. The limited Funding Opportunity Announcement (FOA) invites an application to support the Data Coordinating Center (DCC) for the Cardiothoracic Surgical Trials Network (CTSN). A separate FOA (RFA-HL-19-009) seeks applications for Linked Clinical Research Centers (LCRCs). The goals of the CTSN renewal are to: (1) conduct collaborative randomized controlled trials (RCTs) and studies that evaluate cross specialty team-based care, interventions and novel therapies in the context of cardiac surgery but with broader relevance to cardiology and neurology; (2) utilize these findings to improve patient outcomes, and influence clinical practice, with benefits that are translatable to the general population; (3) conduct implementation research alongside RCTs to understand the best strategies for optimal uptake and sustainability and to bolster translation in areas of high disease burden; and (4) foster the next generation of clinical and implementation researchers.
Funding Opportunity PAR-18-789 from the NIH Guide for Grants and Contracts. The goals of this initiative are to discover allelic variants, genomic alterations, and functional changes associated with addictive behaviors in non-human animals through systems studies that employ genetic and genomics strategies. We also encourage proposals that take genetic and/or genomics approaches to integrate data, delineate gene networks, and uncover the function of known or newly discovered genetic or epigenetic variants.
Notice NOT-TR-18-026 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-18-788 from the NIH Guide for Grants and Contracts. The intent of this Funding Opportunity Announcement (FOA) is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment and treatment monitoring for diseases and conditions in the oral cavity and oropharynx.
Funding Opportunity PAR-18-787 from the NIH Guide for Grants and Contracts. The intent of this Funding Opportunity Announcement (FOA) is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment and treatment monitoring for diseases and conditions in the oral cavity and oropharynx.
Notice NOT-AI-18-031 from the NIH Guide for Grants and Contracts
Notice NOT-DK-18-017 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HL-19-017 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI SBIR Phase IIB Bridge Award is to facilitate and accelerate the capital-intensive steps that are required to transition SBIR/STTR Phase II projects to the commercialization stage by promoting partnerships between SBIR/STTR Phase II awardees and third-party investors and/or strategic partners. Applicants must submit a Commercialization Plan, which should include details on any independent third-party funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NHLBI funds being requested throughout the Phase IIB Bridge Award project period. Projects proposed in response to this FOA must relate to the NHLBI mission and require eventual Federal regulatory approval/clearance. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate, but are not required.
Funding Opportunity RFA-HL-19-018 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI SBIR Phase IIB Small Market Award is to provide support to Phase II SBIR or STTR awardees that are developing NHLBI mission-related products that address a rare disease or young pediatric populations. The goal of this FOA is for these products to be further validated so that development can continue with private funding after NHLBI support ends. Applicants must submit a Commercialization Plan that includes details on any independent third-party funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will be equal to or greater than one-third of the NHLBI funds being requested throughout the project period. Projects proposed in response to this FOA must require eventual Federal regulatory approval/clearance, and may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate, but are not required.
Funding Opportunity PA-18-785 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to encourage Small Business Innovation Research (SBIR) applications from eligible small business concerns proposing to design and produce a non-invasive, discreet, wearable device to monitor blood alcohol levels in real time. Methods that quantify alcohol in blood or interstitial fluid as opposed to detection of alcohol that has exuded through the skin are of highest priority.
Funding Opportunity PA-18-786 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to encourage Small Business Innovation Research (SBIR) applications from eligible small business concerns proposing to design and produce a non-invasive, discreet, wearable device to monitor blood alcohol levels in real time. Methods that quantify alcohol in blood or interstitial fluid as opposed to detection of alcohol that has exuded through the skin are of highest priority.
Funding Opportunity PA-18-784 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support functional microbiome research focused on understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral, including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) biology and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, in vivo and/or ex vivo models that focus on the mechanistic and functional involvement of the microbiome and their components in the modulation or activation of host pathways. The goal is to provide the critical knowledge to guide early translational approaches for better understanding and treatment of HLBS conditions in adults and children. This FOA encourages multidisciplinary collaborations among scientists in a wide range of disciplines including (but not limited to) cardiology, pulmonology, hematology, sleep science, circadian biology, immunology, '-omic' sciences, microbiology, microbial ecology, biotechnology, and bioinformatics.
Funding Opportunity RFA-OD-18-005 from the NIH Guide for Grants and Contracts. The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in research in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence.
Funding Opportunity RFA-OD-18-006 from the NIH Guide for Grants and Contracts. The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in research in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence
Funding Opportunity RFA-OD-18-008 from the NIH Guide for Grants and Contracts. The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. The program is designed to facilitate a timely transition from a mentored postdoctoral research position to a stable independent research position with independent NIH or other independent research support at an earlier stage than is currently the norm
Funding Opportunity RFA-OD-18-007 from the NIH Guide for Grants and Contracts. The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. The program is designed to facilitate a timely transition from a mentored postdoctoral research position to a stable independent research position with independent NIH or other independent research support at an earlier stage than is currently the norm.
Funding Opportunity RFA-AG-19-005 from the NIH Guide for Grants and Contracts. Deprescribing, the cessation of long-term therapy under clinician supervision, is a fundamental technique of geriatric practice and palliative medicine to address inappropriate medication use and/or polypharmacy common among older adults with multimorbidity. Important research gaps remain whose resolution may improve approaches to deprescribing and may improve health outcomes by optimizing the goal-directed care of older adults with multiple chronic conditions. This FOA is intended to support a collaborative network to advance scientific research into techniques and outcomes of deprescribing medications for prevention and treatment of older adults with multiple chronic conditions. This network should address the scientific, safety, ethical, and logistical challenges of deprescribing trials and may incorporate focused attention to other relevant and well-justified topics, such as the risks and benefits of target medications, or alternative approaches that may substitute for the deprescribed drugs. This FOA will support the establishment and initial operations of a network over the 5-year grant period including development of collaborations, resources, and infrastructure.